Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Vincenza Snow"'
Autor:
Mark H. Rozenbaum, Erica Chilson, Raymond Farkouh, Liping Huang, Alejandro Cane, Adriano Arguedas, Maria J. Tort, Vincenza Snow, Ahuva Averin, Derek Weycker, Dhwani Hariharan, Mark Atwood
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 4, Pp 745-760 (2024)
Abstract Introduction A 20-valent pneumococcal conjugate vaccine (PCV20) was recently recommended for use among US children. We evaluated the cost-effectiveness of PCV20 among children aged 6 years with chronic medical conditions (CMC+) and children
Externí odkaz:
https://doaj.org/article/b712d8278380477ba2012c98d05adfdf
Autor:
Matt Wasserman, Ruth Chapman, Rotem Lapidot, Kelly Sutton, Desmond Dillon-Murphy, Shreeya Patel, Erica Chilson, Vincenza Snow, Raymond Farkouh, Stephen Pelton
Publikováno v:
Emerging Infectious Diseases, Vol 27, Iss 6, Pp 1627-1636 (2021)
Pneumococcal conjugate vaccines (PCVs) have been used in the United States since 2000. To assess the cumulative 20-year effect of PCVs on invasive pneumococcal disease (IPD) incidence among children 282,000 cases of IPD, including ≈16,000 meningiti
Externí odkaz:
https://doaj.org/article/56b656ace98144438f269a98cf699d40
Preferences for Adult Pneumococcal Vaccine Recommendations Among United States Health Care Providers
Autor:
Patricia Sacco, Kelley Myers, Christine Poulos, Carolyn Sweeney, Kelly Hollis, Vincenza Snow, Jeffrey T. Vietri
Publikováno v:
Infectious Diseases and Therapy, Vol 8, Iss 4, Pp 657-670 (2019)
Abstract Introduction In 2014, the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) recommended 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysacc
Externí odkaz:
https://doaj.org/article/4a62e87914cc46a4a038a418f8e046c3
Autor:
John M. McLaughlin, David L. Swerdlow, Farid Khan, Oliver Will, Aaron Curry, Vincenza Snow, Raul E. Isturiz, Luis Jodar
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 4, Pp 841-849 (2019)
Background: In September 2014, 13-valent pneumococcal conjugate vaccine (PCV13) was universally recommended for all US adults aged ≥65 years. Adult PCV13 coverage, including whether disparities in uptake exist, however, is not well-described. Metho
Externí odkaz:
https://doaj.org/article/81e189dc97c64eb6b52bdf6b21650442
Autor:
Raul E. Isturiz, Cassandra Hall-Murray, John M. McLaughlin, Vincenza Snow, Beate Schmoele-Thoma, Chris Webber, Allison Thompson, Daniel A Scott
Publikováno v:
Expert Review of Vaccines, Vol 17, Iss 1, Pp 45-55 (2018)
Introduction; Adults, particularly those with underlying chronic conditions, eg, cardiovascular, liver, and pulmonary diseases and diabetes mellitus, have a persistent pneumococcal disease burden. Thirteen-valent pneumococcal conjugate vaccine (PCV13
Externí odkaz:
https://doaj.org/article/6f6cee40e7e942f1b353c1ef8c70e624
Publikováno v:
Journal of Primary Care & Community Health, Vol 2 (2011)
Purpose: The purpose of this pilot study was to create a comprehensive pain management educational toolkit for the primary care physician that offers guidance on current standards of care and quality improvement techniques to help curb educational an
Externí odkaz:
https://doaj.org/article/feaeaf07a5f74d18a79da5b4cb92af9c
Autor:
Liping, Huang, Matt, Wasserman, Lindsay, Grant, Raymond, Farkouh, Vincenza, Snow, Adriano, Arguedas, Erica, Chilson, Reiko, Sato, Johnna, Perdrizet
Publikováno v:
Vaccine. 40:4700-4708
The addition of pneumococcal conjugate vaccines (PCVs) to the United States (US) national immunization program led to significant reductions in incidence, mortality, and associated sequelae caused by pneumococcal disease (PD) in children and adults t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2016501618ea1bf6f368eb519f2d3d46
https://doi.org/10.1016/j.vaccine.2022.06.024
https://doi.org/10.1016/j.vaccine.2022.06.024
Autor:
Raymond Farkouh, Kelly Sutton, Vincenza Snow, Stephen I. Pelton, Erica Chilson, Desmond Dillon-Murphy, Matt Wasserman, Shreeya Patel, Ruth Chapman, Rotem Lapidot
Publikováno v:
Emerging Infectious Diseases, Vol 27, Iss 6, Pp 1627-1636 (2021)
Emerging Infectious Diseases
Emerging Infectious Diseases
Pneumococcal conjugate vaccines (PCVs) have been used in the United States since 2000. To assess the cumulative 20-year effect of PCVs on invasive pneumococcal disease (IPD) incidence among children 282,000 cases of IPD, including ≈16,000 meningiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::110fc13718f2a9960baa7d1063f573a0
https://wwwnc.cdc.gov/eid/article/27/6/20-4238_article
https://wwwnc.cdc.gov/eid/article/27/6/20-4238_article
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 45:270-281
What is known and objective This review describes invasive meningococcal disease (IMD) epidemiology in the United States, provides a brief overview of available meningococcal vaccines and discusses meningococcal serogroup B (MenB) vaccine development
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4b23fdc46e98bd0059f46a7a5620001
https://doi.org/10.1111/jcpt.13083
https://doi.org/10.1111/jcpt.13083
Preferences for Adult Pneumococcal Vaccine Recommendations Among United States Health Care Providers
Autor:
Christine Poulos, Vincenza Snow, Jeffrey Vietri, Carolyn Sweeney, Kelley H. Myers, Patricia Sacco, Kelly Hollis
Publikováno v:
Infectious Diseases and Therapy, Vol 8, Iss 4, Pp 657-670 (2019)
Infectious Diseases and Therapy
Infectious Diseases and Therapy
Introduction In 2014, the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) recommended 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89dd7a123395e29aa2b76f68e0b874c9
http://link.springer.com/article/10.1007/s40121-019-00266-5
http://link.springer.com/article/10.1007/s40121-019-00266-5